The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

Breast Cancer

Interventions

DRUG

Hespiridin and Diosmin

Daflon® (50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet)

All Listed Sponsors

lead

Alexandria University

OTHER